JFG
LYEL icon

Jefferies Financial Group’s Lyell Immunopharma LYEL Stock Holding History

Jefferies Financial Group’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-816
Closed -$10.4K – 1843
2024
Q4 		$10.4K Buy
+816
New +$16.2K ﹤0.01% 1539

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Jefferies Financial Group's LYEL Position: Q1 2025 in Review

Jefferies Financial Group sold out of Lyell Immunopharma (LYEL) in Q1 2025, closing a stake of 816 shares — an estimated $10.4K sold.

Jefferies Financial Group first reported a position in LYEL in Q4 2024 and held it in 1 quarter. The position peaked at $10.4K in Q4 2024. 112 funds tracked by Wall St. Rank hold LYEL as of Q1 2025.

  • Jefferies Financial Group reported no remaining Lyell Immunopharma position as of Q1 2025 after selling out during the quarter.
  • Jefferies Financial Group sold 816 Lyell Immunopharma shares in Q1 2025, an estimated $10.4K.
  • Jefferies Financial Group first reported a position in Lyell Immunopharma in Q4 2024 and held it in 1 quarter.
  • Jefferies Financial Group's Lyell Immunopharma position peaked at $10.4K in Q4 2024.
  • 112 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2025.

Based on Jefferies Financial Group's 13F filing for Q1 2025, filed 8 May 2025.